Biontech and Pfizer wanted to obtain a ruling that three of Curevac’s US patents are not infringed by their Covid-19 vaccine.
(Photo: dpa)
Frankfurt The biotech company Biontech is taking action against the patent allegations of its competitor Curevac. The Mainz-based company announced on Tuesday that Biontech and its US partner Pfizer had filed a declaratory action with the federal district court in Massachusetts.
The two companies want to obtain a ruling that determines that three of Curevac’s US patents are not infringed by their Covid-19 vaccine Comirnaty, it said. Rather, this is based on Biontech’s proprietary mRNA technology, say the Mainz-based vaccine manufacturer and Pfizer.
Biontech had already announced that it would examine all legal options after Curevac’s lawsuit. At the beginning of the month, the Tübingen-based biotech company announced that it saw its patents being infringed by the Mainz-based competitor’s vaccine, which had sold billions of copies, and had therefore filed a lawsuit against Biontech and two of the company’s subsidiaries at the Düsseldorf Regional Court.
Curevac is demanding “fair compensation” for breaching a number of its intellectual property rights used in the manufacture and sale of Comirnaty by Biontech and Pfizer. Biontech had rejected the allegations.
Top jobs of the day
Find the best jobs now and
be notified by email.
More: With the lawsuit against Biontech, Curevac is threatened with serious damage to its image